Bifunctional protacs and molecular glue compounds and methods of use thereof
By designing PROTACs and molecular glue compounds with specific structures, the toxicity problem of CDK9 inhibitors and the targeting problem of molecular glue compounds have been solved, enabling highly efficient targeted therapy for diseases such as cancer.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- BYRON KRAFT THERAPEUTICS LLC
- Filing Date
- 2024-10-09
- Publication Date
- 2026-06-19
AI Technical Summary
In the prior art, the development of CDK9 inhibitors is hampered by complex toxicity characteristics related to activity, and the targeting and selectivity of molecular compounds are insufficient to meet the needs of treating certain diseases such as cancer.
We design and synthesize PROTAC and molecular glue compounds with specific structures, including conjugated E3 ubiquitin ligases, bivalent linkers, and CDK inhibitors, to target the degradation of specific proteins, providing greater selectivity and therapeutic efficacy.
It enables highly effective targeted therapy for diseases such as cancer by disrupting multiple copies of phenotypic proteins through transient binding and polyubiquitination, providing higher sensitivity and therapeutic potential.
Smart Images
Figure 1 Figure 2